The EDELIFE clinical trial, the first investigation of a signalling molecule to treat in utero a human developmental genetic disorder
Schneider H, Hadj-Rabia S, Faschingbauer F, Bodemer C, Grange DK, Guillén-Navarro E, Tadini G, Clarke A (2024)
Publication Language: English
Publication Type: Journal article, Original article
Publication year: 2024
Journal
Book Volume: 32
Pages Range: 736-737
Authors with CRIS profile
Involved external institutions
Cardiff University
United Kingdom (GB)
Hôpital Necker-Enfants malades
France (FR)
Hospital Clínico Universitario Virgen de la Arrixaca
Spain (ES)
Washington University in St. Louis
United States (USA) (US)
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Italy (IT)
United Kingdom (GB)
Hôpital Necker-Enfants malades
France (FR)
Hospital Clínico Universitario Virgen de la Arrixaca
Spain (ES)
Washington University in St. Louis
United States (USA) (US)
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Italy (IT)
How to cite
APA:
Schneider, H., Hadj-Rabia, S., Faschingbauer, F., Bodemer, C., Grange, D.K., Guillén-Navarro, E.,... Clarke, A. (2024). The EDELIFE clinical trial, the first investigation of a signalling molecule to treat in utero a human developmental genetic disorder. European Journal of Human Genetics, 32, 736-737.
MLA:
Schneider, Holm, et al. "The EDELIFE clinical trial, the first investigation of a signalling molecule to treat in utero a human developmental genetic disorder." European Journal of Human Genetics 32 (2024): 736-737.
BibTeX: Download